IRLAB Therapeutics AB (publ)

kr 2.05As of Sun 8 Nov 2026, 12:00 UTC
STO:IRLAB-AHealthcare
Country Sweden
PE (Fwd) •••
TSR 10Y CAGR (15.68%)
Div yield —
ROE (155.06%)
Biotechnology
Beta (5Y) 0.59
PE TTM —
TSR TTM (15.87%)
Mkt cap kr 304.9M
ROIC (28.50%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
kr 2.08
1.41%
(10.27%)
Hold 10|4|10|1|4
4Q25
1Q26
2Q26
3Q26
Earnings per sharekr
0.02
0.03
0.03
0.03
5.49%
13.97%
29.70%
21.05%
Revenuekr M
18.95
19.66
20.72
20.92
10.08%
11.64%
18.87%
16.37%
Peers (US$30.82M)
Cap (US$)
PE
34.74M
—
Capital
TTM
5Y
10Y
Leveragex
0.922
0.090
0.090
EBIT/Intx
0.470
0.104
0.109
Own earn%
21.14
(136.71)
(124.12)
Sh yield%
43.36
8.07
6.74
Owners
Insiders/Inst%
5.89
25.05
Short interest%
2.29
SBC / revenue%
2.53
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
15
Op margin range%
26–33
$1 testx
—
Incr. ROIC%
0